https://www.live-feeds.com/feed/pfizer-ceo-says-covid-is-irrelevant-he-s-betting-on-cancer-and-weight-loss-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/pfizer-ceo-says-covid-is-irrelevant-he-s-betting-on-cancer-and-weight-loss-drugshttps://www.live-feeds.com/feed/pfizer-ceo-says-covid-is-irrelevant-he-s-betting-on-cancer-and-weight-loss-drugs#u183349Sat, 07 Nov 2026 02:31:46 +0000Pfizer increased its 2026 forecast due to strong sales of newer products, including cancer and weight-loss drugs. The company's blood thinner drug, Eliquis, also drove the Q3 beat. Pfizer CEO Albert Bourla is betting on these new products to drive growth post-pandemic. The company raised its full-year outlook and appointed a new CFO, Cecile Guegan.Why it mattersPfizer's growth strategy focuses on new products, including cancer and weight-loss drugs, as COVID-19 sales decline. The company's Q3 results beat expectations, driven by Eliquis and other newer products. This momentum is